اَخر الأخبار
Sage Therapeutics to end Huntington’s disease trial after key therapy fails again
It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease.
For more details: Click here